Long journey on the role of long non-coding RNA (lncRNA) in acute kidney injury (AKI)

• Published in: Pathology, research and practice research and practice, 2024-11, Vol.263, p.155591, Article 155591
• Main Authors: Alsaab, Hashem O., Alaqile, Atheer F., Alsaeedi, Rahaf N., Alzahrani, Mohammad S., Almutairy, Bandar
• Format: Article
• Language: English
• Subjects: Acute kidney injury (AKI); Acute Kidney Injury - genetics; Acute Kidney Injury - metabolism; Animals; Biomarkers - metabolism; Gene Expression Regulation; Gene Regulatory Networks; Humans; Long non-coding RNAs (lncRNAs); Pathogenesis; Regeneration; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; Treatment
• ISSN: 0344-0338; 1618-0631; 1618-0631
• DOI: 10.1016/j.prp.2024.155591

Acute kidney injury (AKI) has a high rate of morbidity, death, and medical expenses, making it a worldwide public health problem. There are still few viable treatment plans for AKI despite medical advancements. A subclass of non-coding RNAs with over 200 nucleotides in length, long non-coding RNAs (lncRNAs) have a wide range of biological roles. Lately, lncRNAs have become important mediators of AKI and prospective biomarkers. However, current studies show that, via constructing the lncRNA/microRNA/target gene regulatory axis, abnormal expression of lncRNAs has been connected to significant pathogenic processes associated with AKI, such as the inflammatory response, cell proliferation, and apoptosis. In order to compete with mRNAs for binding to the same miRNAs and affect the expression of transcripts targeted by miRNAs, lncRNAs may function as competing endogenous RNAs (ceRNAs). The most widely used approach for researching the biological roles of lncRNAs is the construction of ceRNA regulation networks. Our goal in this article is to deliver an updated review of lncRNAs in AKI and to provide more knowledge on their possible applications as therapeutic targets and AKI biomarkers.